{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:10:35Z","timestamp":1793333435935,"version":"4.5.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":114,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s13311-023-01380-6","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T12:03:33Z","timestamp":1683547413000},"page":"1055-1065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["New Approaches to the Treatment of Frontotemporal Dementia"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5405-5985","authenticated-orcid":false,"given":"Kyra D.","family":"Neylan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-023-01380-6_bib1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1474-4422(05)70223-4","article-title":"Frontotemporal dementia","volume":"4","author":"Neary","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib2","doi-asserted-by":"crossref","first-page":"e1047","DOI":"10.1212\/WNL.0000000000005163","article-title":"Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration","volume":"90","author":"Seo","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib3","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/09540261.2013.776523","article-title":"The epidemiology of frontotemporal dementia","volume":"25","author":"Onyike","year":"2013","journal-title":"Int Rev Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib4","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/brain\/awr179","article-title":"Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia","volume":"134","author":"Rascovsky","year":"2011","journal-title":"Brain"},{"key":"10.1007\/s13311-023-01380-6_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00401-007-0236-3","article-title":"Frontotemporal lobar degeneration: clinical and pathological relationships","volume":"114","author":"Snowden","year":"2007","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-023-01380-6_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib7","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1212\/WNL.51.4.978","article-title":"Emergence of artistic talent in frontotemporal dementia","volume":"51","author":"Miller","year":"1998","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib8","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2017.19501","article-title":"Artistic renaissance in frontotemporal dementia","volume":"319","author":"Erkkinen","year":"2018","journal-title":"JAMA"},{"key":"10.1007\/s13311-023-01380-6_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2023.0001","article-title":"Prevalence, timing, and network localization of emergent visual creativity in frontotemporal dementia","author":"Friedberg","year":"2023","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3389\/fneur.2018.00692","article-title":"Clinical, anatomical, and pathological features in the three variants of primary progressive aphasia: a review","volume":"9","author":"Montembeault","year":"2018","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S1474-4422(12)70099-6","article-title":"The non-fluent\/agrammatic variant of primary progressive aphasia","volume":"11","author":"Grossman","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-023-01380-6_bib13","first-page":"e402","article-title":"Amyotrophic lateral sclerosis-frontotemporal dementia: shared and divergent neural correlates across the clinical spectrum","volume":"98","author":"Cividini","year":"2021","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib14","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S0140-6736(15)00461-4","article-title":"Frontotemporal dementia","volume":"386","author":"Bang","year":"2015","journal-title":"Lancet"},{"key":"10.1007\/s13311-023-01380-6_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/nmt.14.34","article-title":"Frontotemporal dementia: diagnosis, deficits and management","volume":"4","author":"Bott","year":"2014","journal-title":"Neurodegener Dis Manag"},{"key":"10.1007\/s13311-023-01380-6_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.psc.2020.02.006","article-title":"Frontotemporal dementia: neuropathology, genetics, neuroimaging, and treatments","volume":"43","author":"Younes","year":"2020","journal-title":"Psychiatr Clin North Am"},{"key":"10.1007\/s13311-023-01380-6_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1212\/01.wnl.0000200048.53766.b4","article-title":"A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia","volume":"66","author":"Morita","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/brain\/awl030","article-title":"Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3","volume":"129","author":"Vance","year":"2006","journal-title":"Brain"},{"key":"10.1007\/s13311-023-01380-6_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuron.2011.09.011","article-title":"Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS","volume":"72","author":"DeJesus-Hernandez","year":"2011","journal-title":"Neuron"},{"key":"10.1007\/s13311-023-01380-6_bib20","unstructured":"Gossye H, Engelborghs S, Van Broeckhoven C, van der Zee J. C9orf72 frontotemporal dementia and\/or amyotrophic lateral sclerosis. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews((R)). Seattle (WA); 1993."},{"key":"10.1007\/s13311-023-01380-6_bib21","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1474-4422(21)00341-0","article-title":"Advances and controversies in frontotemporal dementia: diagnosis, biomarkers, and therapeutic considerations","volume":"21","author":"Boeve","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1212\/WNL.0000000000004840","article-title":"Progranulin: functions and neurologic correlations","volume":"90","author":"Townley","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib23","unstructured":"Hsiung GYR, Feldman HH. GRN frontotemporal dementia. In: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, et al., editors. GeneReviews((R)). Seattle (WA); 1993."},{"key":"10.1007\/s13311-023-01380-6_bib24","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/brain\/awm320","article-title":"A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series","volume":"131","author":"Beck","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-023-01380-6_bib25","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/brain\/awn012","article-title":"Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study","volume":"131","author":"Le Ber","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-023-01380-6_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.702788","article-title":"Human tau isoforms and proteolysis for production of toxic tau fragments in neurodegeneration","volume":"15","author":"Boyarko","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1007\/s13311-023-01380-6_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(13)70090-5","article-title":"Tau pathology and neurodegeneration","volume":"12","author":"Spillantini","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S1474-4422(19)30394-1","article-title":"Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study","volume":"19","author":"Moore","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib29","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/B978-0-444-64076-5.00027-2","article-title":"Frontotemporal dementia","volume":"148","author":"Deleon","year":"2018","journal-title":"Handb Clin Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/21678421.2020.1733019","article-title":"Mixed neuropathology in frontotemporal lobar degeneration","volume":"21","author":"Pennington","year":"2020","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"10.1007\/s13311-023-01380-6_bib31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40478-017-0471-3","article-title":"Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration","volume":"5","author":"Yousef","year":"2017","journal-title":"Acta Neuropathol Commun"},{"key":"10.1007\/s13311-023-01380-6_bib32","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00401-017-1679-9","article-title":"Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration","volume":"134","author":"Lee","year":"2017","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-023-01380-6_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-51140-1_11","article-title":"Progressive supranuclear palsy and corticobasal degeneration","volume":"1281","author":"Coughlin","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1007\/s13311-023-01380-6_bib34","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ana.22424","article-title":"Clinicopathological correlations in corticobasal degeneration","volume":"70","author":"Lee","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneurol.2014.78","article-title":"The role of FUS gene variants in neurodegenerative diseases","volume":"10","author":"Deng","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/01.JGP.0000231744.69631.33","article-title":"Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia","volume":"15","author":"Mendez","year":"2007","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib37","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1447-0594.2012.00956.x","article-title":"Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms","volume":"13","author":"Kimura","year":"2013","journal-title":"Geriatr Gerontol Int"},{"key":"10.1007\/s13311-023-01380-6_bib38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1212\/WNL.57.3.467","article-title":"Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy","volume":"57","author":"Litvan","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1474-4422(12)70320-4","article-title":"Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Boxer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib40","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3233\/JAD-2010-101632","article-title":"Memantine in behavioral variant frontotemporal dementia: negative results","volume":"23","author":"Vercelletto","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"10.1007\/s13311-023-01380-6_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.694872","article-title":"Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: a consensus statement of the CurePSP Centers of Care","volume":"12","author":"Bluett","year":"2021","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/WNF.0000000000000469","article-title":"Behavioral and cognitive response to selective serotonin reuptake inhibitors in frontotemporal lobar degeneration: a systematic review and meta-analysis","volume":"44","author":"Nisar","year":"2021","journal-title":"Clin Neuropharmacol"},{"key":"10.1007\/s13311-023-01380-6_bib43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/JGP.0b013e31823033f3","article-title":"Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia","volume":"20","author":"Herrmann","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib44","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/YIC.0000000000000023","article-title":"A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?","volume":"29","author":"Sanchez","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1007\/s13311-023-01380-6_bib45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/gps.774","article-title":"Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration","volume":"18","author":"Pijnenburg","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib46","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11940-014-0319-0","article-title":"Treatment of frontotemporal dementia","volume":"16","author":"Tsai","year":"2014","journal-title":"Curr Treat Options Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","article-title":"Drug-induced parkinsonism","volume":"8","author":"Shin","year":"2012","journal-title":"J Clin Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ph14010029","article-title":"Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis","volume":"14","author":"Cho","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1007\/s13311-023-01380-6_bib49","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/jnnp-2022-329024","article-title":"Effect of sodium phenylbutyrate\/taurursodiol on tracheostomy\/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial","volume":"93","author":"Paganoni","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib50","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon","year":"2009","journal-title":"Brain"},{"key":"10.1007\/s13311-023-01380-6_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.14802\/jmd.18051","article-title":"Pseudobulbar affect in parkinsonian disorders: a review","volume":"12","author":"Hakimi","year":"2019","journal-title":"J Mov Disord"},{"key":"10.1007\/s13311-023-01380-6_bib52","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/JCP.0b013e31823f91b9","article-title":"Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine","volume":"32","author":"Poetter","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s13311-023-01380-6_bib53","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/WAD.0000000000000161","article-title":"Low-dose lithium treatment for agitation and psychosis in Alzheimer disease and frontotemporal dementia: a case series","volume":"31","author":"Devanand","year":"2017","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1007\/s13311-023-01380-6_bib54","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/153331750201700504","article-title":"Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration","volume":"17","author":"Chow","year":"2002","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1007\/s13311-023-01380-6_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1155\/2013\/547853","article-title":"Topiramate for abnormal eating behaviour in frontotemporal dementia","volume":"27","author":"Singam","year":"2013","journal-title":"Behav Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib56","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1479-8301.2012.00429.x","article-title":"Managing abnormal eating behaviours in frontotemporal lobar degeneration patients with topiramate","volume":"13","author":"Shinagawa","year":"2013","journal-title":"Psychogeriatrics"},{"key":"10.1007\/s13311-023-01380-6_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1176\/jnp.2010.22.1.19","article-title":"Frontotemporal dementia and pharmacologic interventions","volume":"22","author":"Kaye","year":"2010","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1007\/s13311-023-01380-6_bib58","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.4088\/JCP.v69n1219a","article-title":"Stimulant treatment of frontotemporal dementia in 8 patients","volume":"69","author":"Huey","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib59","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/alz.12001","article-title":"Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration","volume":"16","author":"Casaletto","year":"2020","journal-title":"Alzheimers Dement"},{"key":"10.1007\/s13311-023-01380-6_bib60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1155\/2013\/824302","article-title":"Treatment for apraxia of speech in nonfluent variant primary progressive aphasia","volume":"26","author":"Henry","year":"2013","journal-title":"Behav Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib61","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/CIA.S178878","article-title":"Investigating the utility of teletherapy in individuals with primary progressive aphasia","volume":"14","author":"Dial","year":"2019","journal-title":"Clin Interv Aging"},{"key":"10.1007\/s13311-023-01380-6_bib62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1044\/gero17.2.37","article-title":"Thinking outside the stroke: treating primary progressive aphasia (PPA)","volume":"17","author":"Khayum","year":"2012","journal-title":"Perspect Gerontol"},{"key":"10.1007\/s13311-023-01380-6_bib63","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.2522\/ptj.20060166","article-title":"Long-term locomotor training for gait and balance in a patient with mixed progressive supranuclear palsy and corticobasal degeneration","volume":"87","author":"Steffen","year":"2007","journal-title":"Phys Ther"},{"key":"10.1007\/s13311-023-01380-6_bib64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0891988707303603","article-title":"Depression in primary progressive aphasia","volume":"20","author":"Medina","year":"2007","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib65","doi-asserted-by":"crossref","DOI":"10.1177\/1533317519895638","article-title":"Primary progressive aphasia education and support groups: a clinical evaluation","volume":"35","author":"Taylor-Rubin","year":"2020","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1007\/s13311-023-01380-6_bib66","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1177\/1471301217699675","article-title":"Development of a psycho-educational support program for individuals with primary progressive aphasia and their care-partners","volume":"18","author":"Morhardt","year":"2019","journal-title":"Dementia (London)"},{"key":"10.1007\/s13311-023-01380-6_bib67","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/JGP.0b013e318233154d","article-title":"The experience of caregiving: differences between behavioral variant of frontotemporal dementia and Alzheimer disease","volume":"20","author":"Wong","year":"2012","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib68","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/gps.4504","article-title":"Effectiveness of respite care in supporting informal caregivers of persons with dementia: a systematic review","volume":"31","author":"Vandepitte","year":"2016","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib69","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.0000000000200063","article-title":"Clinical guidance in neuropalliative care: an AAN position statement","volume":"98","author":"Taylor","year":"2022","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib70","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/jnnp.2010.232637","article-title":"Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives","volume":"82","author":"Bede","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib71","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1034\/j.1600-0404.2001.2000236.x","article-title":"Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia","volume":"103","author":"Bathgate","year":"2001","journal-title":"Acta Neurol Scand"},{"key":"10.1007\/s13311-023-01380-6_bib72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.trci.2017.08.002","article-title":"An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations","volume":"3","author":"Sha","year":"2017","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1007\/s13311-023-01380-6_bib73","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.25584","article-title":"Effect of the histone deacetylase inhibitor FRM-0334 on progranulin levels in patients with progranulin gene haploinsufficiency: a randomized clinical trial","volume":"4","author":"Ljubenkov","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1007\/s13311-023-01380-6_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.586107","article-title":"Anti-sortilin1 antibody up-regulates progranulin via sortilin1 down-regulation","volume":"14","author":"Miyakawa","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1007\/s13311-023-01380-6_bib75","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/acn3.51165","article-title":"Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations","volume":"7","author":"Hinderer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib76","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.neuron.2010.09.034","article-title":"Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin","volume":"68","author":"Hu","year":"2010","journal-title":"Neuron"},{"key":"10.1007\/s13311-023-01380-6_bib77","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1523\/JNEUROSCI.3081-17.2018","article-title":"Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis","volume":"38","author":"Arrant","year":"2018","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-023-01380-6_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.134919","article-title":"Targeting tau: clinical trials and novel therapeutic approaches","volume":"731","author":"VandeVrede","year":"2020","journal-title":"Neurosci Lett"},{"key":"10.1007\/s13311-023-01380-6_bib79","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ncl.2017.01.008","article-title":"Frontotemporal dementia","volume":"35","author":"Olney","year":"2017","journal-title":"Neurol Clin"},{"key":"10.1007\/s13311-023-01380-6_bib80","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib81","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat Med"},{"key":"10.1007\/s13311-023-01380-6_bib82","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-191173","article-title":"Concentration-dependent activity of hydromethylthionine on clinical decline and brain atrophy in a randomized controlled trial in behavioral variant frontotemporal dementia","volume":"75","author":"Shiells","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.1007\/s13311-023-01380-6_bib83","article-title":"A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia","volume":"8","author":"Vivash","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1007\/s13311-023-01380-6_bib84","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00702-014-1315-y","article-title":"Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies","volume":"122","author":"Dai","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"10.1007\/s13311-023-01380-6_bib85","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.25815","article-title":"Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial","volume":"29","author":"Hoglinger","year":"2014","journal-title":"Mov Disord"},{"key":"10.1007\/s13311-023-01380-6_bib86","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib87","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1038\/mtna.2014.30","article-title":"Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies","volume":"3","author":"Sud","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1007\/s13311-023-01380-6_bib88","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-023-01380-6_bib89","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","article-title":"Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial","volume":"20","author":"Hoglinger","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib90","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mdc3.12940","article-title":"Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy","volume":"7","author":"VandeVrede","year":"2020","journal-title":"Mov Disord Clin Pract"},{"key":"10.1007\/s13311-023-01380-6_bib91","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2\/3 trial","volume":"13","author":"Boxer","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-023-01380-6_bib92","doi-asserted-by":"crossref","first-page":"e2635","DOI":"10.1212\/WNL.0000000000010933","article-title":"Neural effects of oxytocin and mimicry in frontotemporal dementia: a randomized crossover study","volume":"95","author":"Oliver","year":"2020","journal-title":"Neurology"},{"key":"10.1007\/s13311-023-01380-6_bib93","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13195-018-0427-2","article-title":"Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)","volume":"10","author":"Finger","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1007\/s13311-023-01380-6_bib94","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028645","article-title":"Differences in peripheral immune system gene expression in frontotemporal degeneration","volume":"101","author":"Sawyer","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1007\/s13311-023-01380-6_bib95","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/jnnp-2012-304644","article-title":"TDP-43 frontotemporal lobar degeneration and autoimmune disease","volume":"84","author":"Miller","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-023-01380-6_bib96","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/brain\/awaa457","article-title":"Glial cells and adaptive immunity in frontotemporal dementia with tau pathology","volume":"144","author":"Hartnell","year":"2021","journal-title":"Brain"},{"key":"10.1007\/s13311-023-01380-6_bib97","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cell.2016.04.001","article-title":"Progranulin deficiency promotes circuit-specific synaptic pruning by microglia via complement activation","volume":"165","author":"Lui","year":"2016","journal-title":"Cell"},{"key":"10.1007\/s13311-023-01380-6_bib98","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-33500-9","article-title":"Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis","volume":"13","author":"Boland","year":"2022","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-023-01380-6_bib99","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s12640-021-00405-2","article-title":"Preclinical validation of a novel oral Edaravone formulation for treatment of frontotemporal dementia","volume":"39","author":"Kelliny","year":"2021","journal-title":"Neurotox Res"},{"key":"10.1007\/s13311-023-01380-6_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.710818","article-title":"A systematic review of transcranial direct current stimulation in primary progressive aphasia: methodological considerations","volume":"13","author":"Coemans","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"10.1007\/s13311-023-01380-6_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10090597","article-title":"Efficacy of noninvasive brain stimulation (tDCS or TMS) paired with language therapy in the treatment of primary progressive aphasia: an exploratory meta-analysis","volume":"10","author":"Nissim","year":"2020","journal-title":"Brain Sci"},{"key":"10.1007\/s13311-023-01380-6_bib102","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3389\/fnhum.2017.00347","article-title":"Baseline performance predicts tDCS-mediated improvements in language symptoms in primary progressive aphasia","volume":"11","author":"McConathey","year":"2017","journal-title":"Front Hum Neurosci"},{"key":"10.1007\/s13311-023-01380-6_bib103","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bandl.2016.05.007","article-title":"Transcranial direct current stimulation for the treatment of primary progressive aphasia: an open-label pilot study","volume":"162","author":"Gervits","year":"2016","journal-title":"Brain Lang"},{"key":"10.1007\/s13311-023-01380-6_bib104","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3233\/JAD-210566","article-title":"Personalized repetitive transcranial magnetic stimulation for primary progressive aphasia","volume":"84","author":"Pytel","year":"2021","journal-title":"J Alzheimers Dis"},{"key":"10.1007\/s13311-023-01380-6_bib105","article-title":"Transcranial stimulation in frontotemporal dementia: a randomized, double-blind, sham-controlled trial","volume":"6","author":"Benussi","year":"2020","journal-title":"Alzheimers Dement (N Y)"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01380-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01380-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01380-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:13:56Z","timestamp":1761808436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1878747923019116"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01380-6","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Approaches to the Treatment of Frontotemporal Dementia","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01380-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}